Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome

Recombinant human soluble thrombomodulin ( rhTM ) is a promising therapeutic natural anticoagulant and is used clinically for the treatment of disseminated intravascular coagulation ( DIC ). Herein is reported the cases of two HUS children treated with rhTM . The patients were diagnosed as having typical HUS on the basis of thrombocytopenia, hemolytic anemia, acute renal failure, and the detection E scherichia coli 0157. I.v. rhTM was started as an anti‐coagulant drug. At 2 days after the first treatment in both patients, fibrin/fibrinogen degradation products and d ‐dimer levels were significantly decreased, and there was a subsequent slight improvement in thrombocytopenia, and a decrease in serum lactate dehydrogenase level. Urinary protein excretion gradually diminished and a decrease in serum creatinine level was observed. The patients did not require dialysis therapy. The present results suggest that rhTM may be a safe and effective treatment for DIC complicated with HUS in children.